Decreased resistin plasmatic concentrations in patients with Alzheimer's disease: A case-control study.
Adipokines
Adiponectin
Alzheimer's disease
Frontotemporal dementia
Leptin
Resistin
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
28
11
2021
revised:
28
07
2022
accepted:
11
11
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
Previous studies suggested a role for adipokines in ageing and in several age-related diseases. The purpose of our study was to further elucidate adipokines involvement in neurodegeneration, investigating adiponectin, leptin and resistin in Alzheimer's disease (AD) and Frontotemporal Dementia (FTD). We enrolled for the study 70 subjects: 26 AD, 21 FTD, and 23 with other neurological (but not neurodegenerative) conditions (CTR, control group). According to a standardized protocol, we measured adipokines plasmatic levels, blood parameters of glucidic and lipidic metabolism, ESR, cerebrospinal fluid (CSF) markers of neurodegeneration (beta-amyloid, total-Tau, phosphorylated-Tau) and anthropometric parameters. In comparison with control group, we found lower resistin concentrations in patients with dementia, and in particular in AD (p < 0.001). In multivariate analysis, AD relative risk was reduced by resistin, when controlling for sex, age and anthropometric/metabolic parameters (RR = 0.71, P < 0.0001). Considering CSF biomarkers, we found a direct correlation between resistin and Aβ
Identifiants
pubmed: 36439765
doi: 10.1016/j.heliyon.2022.e11738
pii: S2405-8440(22)03026-2
pmc: PMC9694389
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e11738Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Int J Mol Sci. 2020 Mar 03;21(5):
pubmed: 32138327
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Metabolism. 2015 Jan;64(1):131-45
pubmed: 25497344
Endocrinology. 2009 Oct;150(10):4643-52
pubmed: 19589870
J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920
pubmed: 15867843
Alzheimers Dement (Amst). 2015 Sep 1;1(3):339-348
pubmed: 26693175
Cell Metab. 2014 Mar 4;19(3):484-97
pubmed: 24606903
Neuropeptides. 2015 Aug;52:73-8
pubmed: 26070219
Endocrinology. 2008 Sep;149(9):4534-43
pubmed: 18499762
Dement Geriatr Cogn Disord. 2009;28(4):281-7
pubmed: 19828948
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Alzheimers Dis. 2018;61(3):1053-1060
pubmed: 29226876
JAMA. 2009 Dec 16;302(23):2565-72
pubmed: 20009056
Drug Des Devel Ther. 2018 Nov 22;12:3999-4021
pubmed: 30538427
Turk J Med Sci. 2015;45(5):1040-6
pubmed: 26738345
J Alzheimers Dis. 2014;41(2):525-33
pubmed: 24625795
Endocrinology. 2007 Jan;148(1):401-10
pubmed: 17038552
Trends Pharmacol Sci. 2015 Jul;36(7):461-70
pubmed: 26022934
Nutrients. 2019 Nov 05;11(11):
pubmed: 31694146
Clin Biochem. 2016 Feb;49(3):213-8
pubmed: 26515085
Mol Neurobiol. 2019 Apr;56(4):3024-3037
pubmed: 30076527
Nat Commun. 2020 Apr 15;11(1):1841
pubmed: 32296068
J Alzheimers Dis. 2015;44(3):809-13
pubmed: 25352450
Ann Neurol. 2020 Sep;88(3):513-525
pubmed: 32557841
J Am Geriatr Soc. 2016 Jun;64(6):1171-7
pubmed: 27321596
Alzheimers Dement. 2013 Jan;9(1):63-75.e2
pubmed: 23305823
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1092-101
pubmed: 16039994
Eur J Pharmacol. 2004 Jun 16;493(1-3):41-4
pubmed: 15189762
Front Endocrinol (Lausanne). 2019 Mar 11;10:137
pubmed: 30915034
PLoS One. 2011;6(5):e20286
pubmed: 21633502
Arch Neurol. 2012 May;69(5):594-600
pubmed: 22213409
Neurology. 2019 Aug 27;93(9):e864-e878
pubmed: 31363056
Int J Appl Basic Med Res. 2017 Jul-Sep;7(3):176-180
pubmed: 28904917
J Alzheimers Dis. 2012;29(1):151-7
pubmed: 22232009
Diabetes. 2013 Jan;62(1):102-14
pubmed: 22961082
Biogerontology. 2017 Aug;18(4):561-580
pubmed: 28421328